HUMAN PAPILLOMAVIRUS (HPV) TYPE 16 VACCINE TRIAL IN COSTA RICA

评价病毒样颗粒人乳头瘤病毒疫苗10年的安全性、有效性和人群有效性/影响。这将包括对疫苗制剂中未包含的HPV类型的有效性评价，当施用少于三剂时观察到的有效性，以及在宫颈外部位的有效性的原理验证评价。探讨与疫苗接种相关的免疫应答、保护的免疫决定因素以及与疫苗接种相关的最低保护水平。评估HPV疫苗接种对细胞学和HPV DNA筛查方案的影响。评价接种人群中HPV-16/18以外HPV类型的自然史。

To evaluate the safety, efficacy, and population effectiveness/impact of a virus-like particle human papillomavirus vaccine over a 10-year period. This will include an evaluation of efficacy against HPV types not included in the vaccine formulation, efficacy observed when fewer than three doses are administered, and a proof-of principle evaluation of efficacy at extracervical sites. To explore immunological responses associated with vaccination, immunological determinants of protection, and minimum protective levels associated with vaccination. To evaluate the impact of HPV vaccination on cytology and HPV DNA based screening programs. To evaluate the natural history of HPV types other than HPV-16/18 in a vaccinated population.